



**COUNCIL OF
THE EUROPEAN UNION**

**Brussels, 12 May 2014
(OR. en)**

9720/14

**Interinstitutional File:
2013/0222 (COD)**

**VOTE 114
INF 180
PUBLIC 119
CODEC 1251**

NOTE

Subject: - Voting result
- Regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use [**First reading**] (**LA + S**)
- Adoption of the legislative act
3311st meeting of the COUNCIL OF THE EUROPEAN UNION
(Foreign Affairs/Trade)
8 May 2014, Brussels

The outcome of voting on the above mentioned legislative act is attached to this note.




Reference documents:

8795/1/14 REV 1
+ REV 1 ADD 1 REV 1
PE-CONS 44/14

approved by Coreper, Part 1, on 30.04.2014

Any statements and/or explanations of vote are available on the Council's website, under "Documents", "Legislative Transparency", "Monthly Summary of Council acts": <http://www.consilium.europa.eu>.

























































Institution: **Council of the European Union**
 Session: **3311**
 Configuration: **Foreign Affairs**
 Item: **2013/0222 (COD)** (Document: 44/14)
 Voting Rule: **qualified majority**
 Subject: Regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use (first reading)

Vote	Members	Votes Cast
 Yes	28	352
 No	0	0
 Abstain	0	0
Not participating	0	0
Total	28	352

Sitting date: **8/05/2014**

Final result



Member State	Weighting	Vote	Member State	Weighting	Vote
 BELGIQUE/BELGIË	12		 LIETUVA	7	
 БЪЛГАРИЯ	10		 LUXEMBOURG	4	
 CESHÁ REPUBLIKA	12		 MAGYARORSZÁG	12	
 DANMARK	7		 MALTA	3	
 DEUTSCHLAND	29		 NEDERLAND	13	
 EESTI	4		 ÖSTERREICH	10	
 ÉIRE/IRELAND	7		 POLSKA	27	
 ΕΛΛΑΔΑ	12		 PORTUGAL	12	
 ESPAÑA	27		 ROMÂNIA	14	
 FRANCE	29		 SLOVENIJA	4	
 HRVATSKA	7		 SLOVENSKO	7	
 ITALIA	29		 SUOMI/FINLAND	7	
 ΚΥΠΡΟΣ	4		 SVERIGE	10	
 LATVIJA	4		 UNITED KINGDOM	29	

* qualified majority is reached if at least 260 votes in favour are cast by at least 15 of the 28 participating Council members

For information: <http://www.consilium.europa.eu/public-vote>